Show simple item record

dc.contributor.authorBergamino Sirvén, M
dc.contributor.authorPernas, S
dc.contributor.authorCheang, MCU
dc.date.accessioned2021-04-08T11:30:49Z
dc.date.available2021-04-08T11:30:49Z
dc.date.issued2021-02-09
dc.identifier.citationCancers, 2021, 13 (4)
dc.identifier.issn2072-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4502
dc.identifier.eissn2072-6694
dc.identifier.doi10.3390/cancers13040691
dc.description.abstractThe rapidly evolving landscape of immuno-oncology (IO) is redefining the treatment of a number of cancer types. IO treatments are becoming increasingly complex, with different types of drugs emerging beyond checkpoint inhibitors. However, many of the new drugs either do not progress from phase I-II clinical trials or even fail in late-phase trials. We have identified at least five areas in the development of promising IO treatments that should be redefined for more efficient designs and accelerated approvals. Here we review those critical aspects of IO drug development that could be optimized for more successful outcome rates in all cancer types. It is important to focus our efforts on the mechanisms of action, types of response and adverse events of these novel agents. The use of appropriate clinical trial designs with robust biomarkers of response and surrogate endpoints will undoubtedly facilitate the development and subsequent approval of these drugs. Further research is also needed to establish biomarker-driven strategies to select which patients may benefit from immunotherapy and identify potential mechanisms of resistance.
dc.formatElectronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleLights and Shadows in Immuno-Oncology Drug Development.
dc.typeJournal Article
dcterms.dateAccepted2021-02-05
rioxxterms.versionAM
rioxxterms.versionofrecord10.3390/cancers13040691
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-02-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancers
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Genomic Analysis – Clinical Trials
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Genomic Analysis – Clinical Trials
pubs.publication-statusPublished
pubs.volume13
pubs.embargo.termsNot known
icr.researchteamGenomic Analysis – Clinical Trials
icr.researchteamGenomic Analysis – Clinical Trialsen_US
dc.contributor.icrauthorCheang, Chonen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0